SONAR
29.5.2024 15:01:32 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced that SonarQube is now available on Google Cloud Marketplace, enabling organizations to accelerate DevOps transformations in the cloud, modernize software development workflows, and deliver higher-quality, secure applications. As companies adopt AI code generation tools, SonarQube ensures that no matter where or how code is developed, it leads to secure, reliable, and maintainable software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529150627/en/
SonarQube is now available on Google Cloud Marketplace. (Photo: Business Wire)
SonarQube’s availability on Google Cloud Marketplace streamlines the process for developers to identify and address potential issues in code early on in the software development lifecycle (SDLC), whether code is human-developed or AI-generated. Developers can now quickly set up SonarQube in their Google Cloud environment to analyze their code quality with simplified billing and scalability that fit their specific needs and budget. Organizations are empowered to accelerate their DevOps transformation initiatives while minimizing risks and ensuring long-term success.
“Bringing SonarQube to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the solution on Google Cloud's trusted, global infrastructure," said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud. “Sonar can now securely scale and support customers on their digital transformation journeys.”
Google Cloud Marketplace lets users quickly deploy functional software packages that run on Google Cloud's infrastructure. Google Cloud Marketplace allows customers to easily start up a familiar software package with services like Compute Engine or Cloud Storage, with no manual configuration required.
Over the last 15 years, Sonar has analyzed more than half a trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. Sonar evaluates code for quality and security issues at two points - in the IDE with SonarLint, and in the Continuous Integration (CI) pipeline, with SonarQube. Sonar’s offering is built on the principles of Clean Code, which is the belief that when code is consistent, intentional, adaptable, and responsible – meaning it is easy to understand and change, operates smoothly at runtime, and contains no technical debt – it results in software that is maintainable, reliable, of quality, and secure.
“Code is one of the most valuable assets in a digital economy. As companies adopt AI and move to the cloud, we want them to continue having seamless access to Sonar’s Clean Code solutions as part of their DevOps environment in the cloud,” said Harry Wang, VP of Strategic Partnerships & Head of Product Marketing at Sonar. “SonarQube availability on Google Cloud Marketplace means that organizations can easily combine Google’s AI capabilities with the familiar Clean Code solution that they trust, to evolve and accelerate software development safely and responsibly.”
SonarQube is an essential tool in the current DevOps toolchain as it reduces issues before they reach production, reduces rollbacks and rework, increases developer velocity, and increases DevOps efficiency and agility. By preventing new issues from entering into production, software becomes easier to maintain and businesses become more competitive, as new features are faster to add.
Key benefits of its availability on Google Cloud Marketplace include:
- Faster Setup: Get up and running with SonarQube quickly and easily, eliminating the need for complex manual installations.
- Seamless Integration: Developers can incorporate SonarQube into their Google Cloud environment with the ease of container deployment on Google Kubernetes Engine (GKE).
- Scalability: Usage of SonarQube can easily scale with Google Cloud’s infrastructure to match evolving needs, no matter the size of the organization or software project.
- Simplified Billing and Cost Effectiveness: Companies can consolidate the purchase of SonarQube with the rest of their cloud spending to achieve better discounts on Google Cloud and reduce administrative overhead.
To learn more about SonarQube, visit here. SonarQube is generally available now on Google Cloud Marketplace.
About Sonar
Sonar is a leading maker of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.
To learn more about Sonar, please visit https://www.sonarsource.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529150627/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom